Drugmaker Harrow slumps after forecasting annual revenue below estimates

Harrow

03/03/2026 10:02

** Shares of ophthalmic drugmaker Harrow HROW.O fall 14.9% to $45.69 premarket

** Co said late on Monday that it expects 2026 revenue in the range of $350 million to $365 million, below analysts' average estimate of $386.25 million, according to LSEG compiled data

** HROW reported Q4 revenue of $89.1 million, beating estimates of $88.45 million

** As of last close, HROW stock up 9.4% YTD

 (Reporting by Padmanabhan Ananthan)

 ((Padmanabhan.Ananthan@thomsonreuters.com))